Publications
2 shownPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,813
- Institution
- Compass Oncology
External Links
Identifiers
- ORCID
- 0000-0003-2700-5656
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.